Evidence map›Paper›PMID 28959424›Full record

ArticleChemical science2017

Recent developments in the use of aza-Heck cyclizations for the synthesis of chiral N-heterocycles.

Nicholas J Race, Ian R Hazelden, Adele Faulkner, John F Bower

Abstract read
In one paragraph

Article in Chemical science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Cyclopropane-FusedJournal of the American Chemical Society · 2022
    Article
  9. Article
  10. Article
  11. Journal of the American Chemical Society · 2022
    Article
  12. Article
  13. Review
  14. Electrophilic Aminating Agents in Total Synthesis.Angewandte Chemie (International ed. in English) · 2021
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Electrochemical Dehydrogenative C(spChemistry (Weinheim an der Bergstrasse, Germany) · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nicholas J RaceSchool of Chemistry , University of Bristol , Bristol , BS8 1TS , UK . Email: john.bower@bris.ac.uk.ORCID 0000-0002-0755-1724
Ian R HazeldenSchool of Chemistry , University of Bristol , Bristol , BS8 1TS , UK . Email: john.bower@bris.ac.uk.
Adele FaulknerSchool of Chemistry , University of Bristol , Bristol , BS8 1TS , UK . Email: john.bower@bris.ac.uk.
John F BowerSchool of Chemistry , University of Bristol , Bristol , BS8 1TS , UK . Email: john.bower@bris.ac.uk.ORCID 0000-0002-7551-8221

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aza-Heck cyclizations are an emerging method for the construction of chiral N-heterocyclic systems. In these processes, an activated N-O bond replaces the C-X bond (X = halide, OTf) used in conventional Heck reactions, with the associated aza-Pd(ii)-intermediate engaging pendant alkenes in a Heck-like manner. This perspective article commences with an historical overview of the area, which stems from Narasaka's seminal studies using oxime esters as the initiating motif. The scope and mechanism of associated chiral N-heterocyclic methodologies are then outlined, including cascade processes that enable diverse alkene 1,2-carboaminations. The recent emergence of new N-O donors and the realization of highly enantioselective aza-Heck cyclizations are then discussed. Collectively, these studies suggest that the aza-Heck approach can underpin a broad family of redox-neutral and enantioselective C-N bond forming processes.

Identifiers

PMID28959424
PMCPMC5606024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.